Covalon Technologies Ltd. (OTCMKTS:CVALF – Get Free Report) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 100 shares, a decline of 92.3% from the December 15th total of 1,300 shares. Based on an average daily volume of 20,700 shares, the short-interest ratio is presently 0.0 days.
Covalon Technologies Stock Performance
Shares of OTCMKTS CVALF traded down $0.09 during mid-day trading on Monday, reaching $2.12. 7,466 shares of the company traded hands, compared to its average volume of 35,381. The company’s fifty day moving average is $2.49 and its two-hundred day moving average is $2.20. Covalon Technologies has a fifty-two week low of $0.74 and a fifty-two week high of $3.08. The stock has a market cap of $58.02 million, a PE ratio of -70.56 and a beta of -0.27.
Covalon Technologies (OTCMKTS:CVALF – Get Free Report) last posted its earnings results on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a negative net margin of 2.94% and a negative return on equity of 4.40%.
Covalon Technologies Company Profile
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.
Read More
- Five stocks we like better than Covalon Technologies
- High Flyers: 3 Natural Gas Stocks for March 2022
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What Are Growth Stocks and Investing in Them
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- ESG Stocks, What Investors Should Know
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Covalon Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covalon Technologies and related companies with MarketBeat.com's FREE daily email newsletter.